198 related articles for article (PubMed ID: 26829939)
21. Synthesis of pregnane derivatives, their cytotoxicity on LNCap and PC-3 cells, and screening on 5alpha-reductase inhibitory activity.
Kim S; Ma E
Molecules; 2009 Nov; 14(11):4655-68. PubMed ID: 19924093
[TBL] [Abstract][Full Text] [Related]
22. Trends in the development of new drugs for treatment of benign prostatic hyperplasia.
Kulig K; Malawska B
Curr Med Chem; 2006; 13(28):3395-416. PubMed ID: 17168713
[TBL] [Abstract][Full Text] [Related]
23. SRD5A1 and SRD5A2 are associated with treatment for benign prostatic hyperplasia with the combination of 5α-reductase inhibitors and α-adrenergic receptor antagonists.
Gu X; Na R; Huang T; Wang L; Tao S; Tian L; Chen Z; Jiao Y; Kang J; Zheng S; Xu J; Sun J; Qi J
J Urol; 2013 Aug; 190(2):615-9. PubMed ID: 23499746
[TBL] [Abstract][Full Text] [Related]
24. Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia.
Andriole G; Bruchovsky N; Chung LW; Matsumoto AM; Rittmaster R; Roehrborn C; Russell D; Tindall D
J Urol; 2004 Oct; 172(4 Pt 1):1399-403. PubMed ID: 15371854
[TBL] [Abstract][Full Text] [Related]
25. Ethanol Extract of
Park E; Lee MY; Seo CS; Jang JH; Kim YU; Shin HK
Nutrients; 2018 Apr; 10(4):. PubMed ID: 29690562
[TBL] [Abstract][Full Text] [Related]
26. Phospholipase A2 degradation products modulate epithelial and stromal 5alpha-reductase activity of human benign prostatic hyperplasia in vitro.
Weisser H; Ziemssen T; Krieg M
Prostate; 2002 Jan; 50(1):4-14. PubMed ID: 11757031
[TBL] [Abstract][Full Text] [Related]
27. Chrysophanic acid reduces testosterone-induced benign prostatic hyperplasia in rats by suppressing 5α-reductase and extracellular signal-regulated kinase.
Youn DH; Park J; Kim HL; Jung Y; Kang J; Jeong MY; Sethi G; Seok Ahn K; Um JY
Oncotarget; 2017 Feb; 8(6):9500-9512. PubMed ID: 27880726
[TBL] [Abstract][Full Text] [Related]
28. Inhibitors of 5alpha-reductase in the treatment of benign prostatic hyperplasia.
Tarter TH; Vaughan ED
Curr Pharm Des; 2006; 12(7):775-83. PubMed ID: 16515494
[TBL] [Abstract][Full Text] [Related]
29. [REVIEW OF CLINICAL STUDIES ON COMBINATION THERAPY OF 5α-REDUCTASE INHIBITORS AND α1-BLOCKERS IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA].
Spivak LG; Lokshin KL; Vinarov AZ
Urologiia; 2015; (4):125-33. PubMed ID: 26665780
[TBL] [Abstract][Full Text] [Related]
30. Cynanchum wilfordii Ameliorates Testosterone-Induced Benign Prostatic Hyperplasia by Regulating 5α-Reductase and Androgen Receptor Activities in a Rat Model.
Lee G; Shin J; Choi H; Jo A; Pan S; Bae D; Lee Y; Choi C
Nutrients; 2017 Sep; 9(10):. PubMed ID: 28953224
[TBL] [Abstract][Full Text] [Related]
31. The clinical development of a 5 alpha-reductase inhibitor, finasteride.
Stoner E
J Steroid Biochem Mol Biol; 1990 Nov; 37(3):375-8. PubMed ID: 1701660
[TBL] [Abstract][Full Text] [Related]
32. Synthesis and biochemical evaluation of (carbamoylalkenyl)phenyloxy carboxylic acid derivatives as non-steroidal 5 alpha-reductase inhibitors.
Kattner L; Göhring S; Hartmann RW
Arch Pharm (Weinheim); 1995 Mar; 328(3):239-45. PubMed ID: 7539251
[TBL] [Abstract][Full Text] [Related]
33. Dutasteride: a novel dual inhibitor of 5alpha-reductase for benign prostatic hyperplasia.
Djavan B; Milani S; Fong YK
Expert Opin Pharmacother; 2005 Feb; 6(2):311-7. PubMed ID: 15757426
[TBL] [Abstract][Full Text] [Related]
34. A preliminary investigation of the enzymatic inhibition of 5alpha-reduction and growth of prostatic carcinoma cell line LNCap-FGC by natural astaxanthin and Saw Palmetto lipid extract in vitro.
Anderson ML
J Herb Pharmacother; 2005; 5(1):17-26. PubMed ID: 16093232
[TBL] [Abstract][Full Text] [Related]
35. Design, synthesis and biological evaluation of novel androst-3,5-diene-3-carboxylic acid derivatives as inhibitors of 5α-reductase type 1 and 2.
Lao K; Sun J; Wang C; Lyu W; Zhou B; Zhao R; Xu Q; You Q; Xiang H
Steroids; 2017 Aug; 124():29-34. PubMed ID: 28549802
[TBL] [Abstract][Full Text] [Related]
36. Medical treatment of benign prostatic hyperplasia: 5 alpha-reductase inhibitors and alpha-adrenergic antagonists.
Monda JM; Oesterling JE
Mayo Clin Proc; 1993 Jul; 68(7):670-9. PubMed ID: 7688840
[TBL] [Abstract][Full Text] [Related]
37. Uvaria rufa Blume attenuates benign prostatic hyperplasia via inhibiting 5α-reductase and enhancing antioxidant status.
Buncharoen W; Saenphet K; Saenphet S; Thitaram C
J Ethnopharmacol; 2016 Dec; 194():483-494. PubMed ID: 27732901
[TBL] [Abstract][Full Text] [Related]
38. Effect of the dual 5alpha-reductase inhibitor PNU 157706 on the growth of dunning R3327 prostatic carcinoma in the rat.
Zaccheo T; Giudici D; di Salle E
J Steroid Biochem Mol Biol; 1998 Feb; 64(3-4):193-8. PubMed ID: 9605414
[TBL] [Abstract][Full Text] [Related]
39. Key targets of hormonal treatment of prostate cancer. Part 2: the androgen receptor and 5alpha-reductase.
Vis AN; Schröder FH
BJU Int; 2009 Nov; 104(9):1191-7. PubMed ID: 19624596
[TBL] [Abstract][Full Text] [Related]
40. Novel C-6 substituted and unsubstituted pregnane derivatives as 5alpha-reductase inhibitors and their effect on hamster flank organs diameter size.
Cabeza M; Zambrano A; Heuze I; Carrizales E; Palacios A; Segura T; Valencia N; Bratoeff E
Steroids; 2009 Oct; 74(10-11):793-802. PubMed ID: 19406144
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
